A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
Open accessThe DOI matches its Crossref record; 327 of the 327 references it cites were found in a registry or an index; 135 of the 655 sources its claims cite were checked for support.
Abstract
Type 2 diabetes (T2D), which has currently become a global pandemic, is a metabolic disease largely characterised by impaired insulin secretion and action. Significant progress has been made in understanding T2D aetiology and pathogenesis, which is discussed in this review. Extrapancreatic pathology is also summarised, which demonstrates the highly multifactorial nature of T2D. Glucagon-like peptide (GLP)-1 is an incretin hormone responsible for augmenting insulin secretion from pancreatic beta-cells during the postprandial period. Given that native GLP-1 has a very short half-life, GLP-1 mimetics with a much longer half-life have been developed, which are currently an effective treatment option for T2D by enhancing insulin secretion in patients. Interestingly, there is continual emerging evidence that these therapies alleviate some of the post-diagnosis complications of T2D. Additionally, these therapies have been shown to induce weight loss in patients, suggesting they could be an alternative to bariatric surgery, a procedure associated with numerous complications. Current GLP-1-based therapies all act as orthosteric agonists for the GLP-1 receptor (GLP-1R). Interestingly, it has emerged that GLP-1R also has allosteric binding sites and agonists have been developed for these sites to test their therapeutic potential. Recent studies have also demonstrated the potential of bi- and tri-agonists, which target multiple hormonal receptors including GLP-1R, to more effectively treat T2D. Improved understanding of T2D aetiology/pathogenesis, coupled with the further elucidation of both GLP-1 activity/targets and GLP-1R mechanisms of activation via different agonists, will likely provide better insight into the therapeutic potential of GLP-1-based therapies to treat T2D.
Overview
CoChat Summary
TL;DR
This narrative review summarizes type 2 diabetes epidemiology, multifactorial aetiology/pathogenesis, extrapancreatic complications, and treatments, with emphasis on GLP-1 receptor-based therapies. It argues that GLP-1R agonists, including emerging allosteric and multi-receptor agonists, may improve glycaemia, weight, and systemic complications, while many mechanistic uncertainties remain.
Key findings
- T2D is described as a global pandemic: ~382 million patients globally in 2013, projected >590 million by 2035 and >700 million by 2045; T2D accounts for ~90% of diabetes cases. Obesity is a major risk factor, reported to increase T2D risk by 90-fold, and genetic susceptibility is supported by ~70% monozygotic twin concordance, 40% lifetime risk with one affected parent, and almost 70% with both parents affected.
- Pathogenesis involves beta-cell dysfunction/apoptosis, peripheral insulin resistance, alpha-cell dysregulation, islet amyloid/IAPP deposition, and a diminished incretin effect, where GLP-1 and GIP account for <20% of insulin release after glucose ingestion in T2D. Extrapancreatic pathology includes cardiovascular disease, diabetic nephropathy, neuropathy, and NAFLD, reported in ~70% of T2D patients.
- GLP-1-based therapies are central: native GLP-1 has a half-life of 1–2 minutes, whereas exenatide has 3.4–4 hours and liraglutide 11–13 hours; GLP-1R agonists augment glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and induce weight loss. In a 160-week liraglutide trial, T2D diagnosis occurred in 2% vs 6% of placebo-treated participants, and time to T2D onset was 2.7x longer with liraglutide.
- Emerging approaches include GLP-1R allosteric agonists (compounds 2 and B) and GLP-1/GIP/glucagon tri-agonists tested in rodents, which improved glycaemia, body weight, and islet architecture. Bariatric surgery can induce T2D remission—one study reported 53% complete remission at three years and another 10% partial remission—but carries complications such as vomiting/dumping syndrome, iron and B12 deficiency, and secondary hyperparathyroidism.
Methods
- Narrative review of published literature on T2D epidemiology, aetiology, pathogenesis, treatments, and future perspectives; no primary data collection or systematic search strategy is described.
- Synthesizes preclinical and clinical evidence, including rodent models, human islets, autopsy studies, and clinical trials; the main analysis is qualitative narrative synthesis.
Limitations
- The paper does not present a formal limitations section; limitations stated in the text include unresolved mechanisms, conflicting findings (e.g., glucolipotoxicity, UCP2, GIP action), uncertainty from undiagnosed diabetes in global prevalence estimates, and the caveat that animal-study observations may have limited clinical implications for humans.
- Evident from the text: as a narrative review, it lacks a described systematic search, inclusion criteria, or formal quality appraisal, and it relies on heterogeneous cited studies without meta-analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
87 Valid · 11 Not valid · 355 Not checked · 7 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“One study demonstrated the importance of genetics in T2D susceptibility independently of the diet as there was a higher prevalence of the disease in the twin population compared to the singleton population77”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Aetiology
What the sources say
- Disputedcites [77] Poulsen, 2009, Diabetes sourceExperimental — accuracy not yet measured
The Discussion confirms that elderly twins had a higher prevalence of type 2 diabetes than singletons. But the Abstract’s Conclusions interpret the finding as evidence for a significant impact of the fetal environment “as opposed to genetics,” contrary to the claim that the comparison demonstrates the importance of genetics. These passages also do not establish independence from diet. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“It has been shown that a high proton motive force (PMF) results in the production of ROS, and as UCP2 activity can lower the PMF by increasing proton leak, it can then lower intracellular ROS, as well as increased production of ROS, is thought to be at least partly dependent on an increased mitochondrial PMF in islet beta-cells.180,183–185”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
What the sources say
- Supportedcites [180] Affourtit, 2011, Free Radic Biol Med source
The Discussion (‘UCP2 function and regulation’) says UCP2 contributes to mitochondrial proton leak. The Discussion (‘GSIS regulation by UCP2’) also describes UCP2 activity as partially dissipating mitochondrial membrane potential, supporting the claimed mechanism. (LLM, conf=0.92)
- Not checked yetcites [183] Pi, 2010, Diabetes Obes Metab source
- Disputedcites [184] Robson-Doucette, 2011, Diabetes sourceExperimental — accuracy not yet measured
The paper’s Results say UCP2 does not contribute to classical proton leak in β-cells, and its Discussion says the increased ROS observed after UCP2 deletion is not caused by reduced proton leak. Although the introduction acknowledges reports of UCP2-facilitated proton leak elsewhere, the paper’s findings contradict that mechanism in the islet β-cell context of the citing sentence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“TNFα secretion from T2D subjects was higher than healthy controls,207,208 and one in vitro study has shown that this myokine impairs beta-cell function.208”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Extrapancreatic Tissues Involvement in T2D: Aetiology/Pathogenesis and Post-Diagnosis Complications
What the sources say
- Supportedcites [207] Ciaraldi, 2016, PLoS One source
The Results/Discussion of our copy state that TNFa secretion is elevated in T2D myotubes relative to non-diabetic cells: Discussion (p. n/a) says 'Our current observation that TNFa secretion, while low, is elevated in T2D myotubes is confirmatory of our earlier results', and the Discussion also summarizes 'our results that secretion of TNFa, IL6 and MCP-1 are all elevated in T2D myotubes'. The Introduction frames the same comparison against cells from non-diabetic (ND) individuals. Note the parallel circulating TNFa difference in Table 2 was not retained after BMI adjustment, but the claim concerns secretion, which the paper supports. (LLM, conf=0.90)
- Disputedcites [208] Bouzakri, 2011, Diabetes sourceExperimental — accuracy not yet measured
Our copy contains no measurement of TNF-α secretion comparing type 2 diabetic subjects with healthy controls; the study is entirely in vitro, using human myotubes rendered insulin resistant by added TNF-α (RESULTS, 'Myokine expression and secretion from human skeletal muscle cells (myotubes) treated with or without TNF-α'). On the contrary point, the DISCUSSION states 'At present, there is little evidence for elevated TNF-α in the skeletal muscle of individuals with type 2 diabetes,' and the background passage (labeled Abstract > CONCLUSIONS in our copy) says the source of increased circulating TNF-α in type 2 diabetes 'remains unclear, but it does not appear to be the muscle itself (18),' with elevated levels in obesity/T2D credited to refs 18-19 rather than shown here. So the muscle-derived ('myokine') elevation the citing sentence attributes to this source is contradicted by our copy; only the separate in vitro β-cell/GSIS impairment finding (TNF-α in TM blunting GSIS, blocked by Ethanercept) is supported. (LLM, conf=0.68)
Checked by a reasoning model — may be wrong.
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“There are a range of effective treatments that reduce hyperglycaemia in T2D patients, which mediate their effects by improving insulin secretion or decreasing peripheral tissue insulin resistance.8”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [8] Raz, 2013, Diabetes Care source
The paper’s sections on individual drug classes describe several effective glucose-lowering treatments with these mechanisms. The sulfonylureas and meglitinides section says they increase insulin secretion, while the PPAR-γ: pioglitazone section says that class lowers blood glucose by reducing insulin resistance and improving insulin sensitivity in muscle. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Better glycaemic control has been reported in T2D patients who have lost weight, and excess body weight is associated with the risk of cardiometabolic complications, which are major causes of morbidity and mortality in T2D and obese individuals.11,12”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Introduction
What the sources say
- Supportedcites [11] Horton, 2010, Diabetes Care source
The Conclusions report that weight loss was associated with better glycemic control in patients with type 2 diabetes. The Results (Regression analysis) specify that this benefit appeared with any weight loss in exenatide-treated patients, but only with weight loss of at least 8% in the sitagliptin and insulin groups. (LLM, conf=0.92)
- Supportedcites [12] Wilding, 2014, Int J Clin Pract source
The ‘Effects on glycaemic control’ section says that weight loss improves glycaemic control in people with T2DM and that those who lose weight are more likely to reach target HbA1c values. The ‘Message for the clinic’ and Introduction also link excess weight to cardiometabolic complications and cardiovascular risk. Page numbers are not available in our copy. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
212 more claims · 48 with their cited sources checked
Create a free account to see all 460 claims and to verify the 520 references still open.
- It may state two separate claims as one. 213
- Probably not a substantial claim. 60
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Emerging evidence supports the concept that deposition of ectopic fat within pancreatic islets, possibly inside β cells themselves, contributes to progressive impairment of β-cell function (which is reversible with weight loss)115 in individuals who are genetically susceptible.116–118”
From Definition and diagnostic criteria of clinical obesity (2025) · cites this paper as [116]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“peripheral insulin resistance is a requisite precursor for the development of this disease.”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Type 2 Diabetes > Pathogenesis
“T2D has been shown to manifest in non-overweight individuals in the absence of insulin resistance, although this is thought to be rare.140”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“exenatide has a half-life of 3.4–4 hours”
§ A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives > Pharmacological Treatments and Lifestyle Changes for T2D
“| Exenatide (Byetta) | Twice daily | 2.4 hours | Yes |”
Citations
Cites
1 retracted
Wang, M., Yao, P., Gao, M., Jin, J., & Yu, Y. (2020) · RSC Advances · doi:10.1039/c9ra10593j · Cited by 9
RetractedSaeedi, P., Petersohn, I., Salpea, P., Malanda, B., Karuranga, S., Unwin, N., Colagiuri, S., Guariguata, L., Motala, A. A., Ogurtsova, K., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.107843 · Cited by 10,792 · cited 6×
“estimated that there will be over 700 million T2D patients worldwide.(1,62) However, as highlighted in”
InfluentialBiochemistry and molecular cell biology of diabetic complications
Brownlee, M. (2001) · Nature · doi:10.1038/414813a · Cited by 9,107
The metabolic phenotype in obesity: Fat mass, body fat distribution, and adipose tissue function
Goossens, G. H. (2017) · Obesity Facts · doi:10.1159/000471488 · Cited by 8,481
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationGlobal estimates of diabetes prevalence for 2013 and projections for 2035
Guariguata, L., Whiting, D. R., Hambleton, I., Beagley, J., Linnenkamp, U., & Shaw, J. E. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2013.11.002 · Cited by 4,642
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Research works printed but not linked: 25
- Thompson, 2013, Clin Exp Pharmacol, 1, 3
- 2010, Clinical Problems Caused by Obesity
- 2012, The Disease Burden Associated with Overweight and Obesity
- Templeman, 2017, J Endocrinol, 2017, 58
- Hu, 2011, Role Diet Lifestyle Genes, 34, 1249
- 2011, Biochemistry
- Karalliedde, 2016, Nephrol Dialysis Transplant, 31, 206
- Ali, 2010, Indian J Med Res, 132, 584
- Mazzola, 2012, Am J Manag Care, 18, 17
- Saeedi, 2019, Diabetes Res Clin Pract, 2, 157
- 1985, Diabetes in America
- Hyttinen, 2003, Nationwide Follow Up Study, 52, 1052
- Torres, 2008, Gastroenterol Hepatol (N Y), 4, 568
- Wilcox, 2005, Clin Biochemist Rev, 26, 19
- Cnop, 2005, Many Differences Few Similarities, 54, S97
- Gerich, 2000, J Clin Endocrinol Metab, 85, 2113
- Ivan Quesada, 2008, J Endocrinol, 2, 68
- Shah, 2000, J Clin Endocrinol Metab, 85, 4053
- Clark, 1988, Diabetes Res, 9, 151
- Perry, 2016, Exerc Immunol Rev, 22, 94
- Keshel, 2015, J Obes Weight Loss Ther, 5, S5
- 2018, Encyclopedia of Signaling Molecules
- Halverson, 1986, Am Surg, 52, 594
- Avinoah, 1992, Surgery, 111, 137
- 2017, Encyclopedia of Signaling Molecules
Cited by
Items 101–200 of 442
Subramanian, V., Bagger, J. I., Harihar, V., Holst, J. J., Knop, F. K., & Villsbøll, T. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00278.2023 · Cited by 12
Effectiveness and clinical benefits of new anti-diabetic drugs: A real life experience
Piazzolla, G., Vozza, A., Volpe, S., Bergamasco, A., Triggiani, V., Lisco, G., Falconieri, M., Tortorella, C., Solfrizzi, V., & Sabbà, C. (2022) · Open Medicine · doi:10.1515/med-2022-0504 · Cited by 10
“and lipotoxicity-induced insulin resistance [26,27], the promotion of browning adipose tissue and fat utilization by M2 macrophages [28], and attenuation of inflammatory responses [29–31].”
BackgroundAl Hayek, A. A., & Al Dawish, M. A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02508-y · Cited by 9
Shahabi, N. A., Hosseini, Z., Aghamolaei, T., Behzad, A., Ghanbarnejad, A., & Dadipoor, S. (2023) · Qualitative Health Research · doi:10.1177/10497323231206964 · Cited by 16
“Type 2 diabetes (T2D), as the most common type of diabetes, has become a global epidemic and is the major burden of healthcare worldwide (Reed et al., 2021).”
BackgroundDiabetes and vitamin D: The effect of insulin sensitivity and gut microbial health
Daley, D. K., & Myrie, S. B. (2024) · Advances in food and nutrition research · doi:10.1016/bs.afnr.2024.04.001 · Cited by 16
Mizani, M. A., Dashtban, A., Pasea, L., Zeng, Q., Khunti, K., Valabhji, J., Mamza, J. B., Gao, H., Morris, T., & Banerjee, A. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004191 · Cited by 16
Perspectives and Preferences of People with Type 2 Diabetes for the Attributes of Weekly Insulin
Gelsey, F. T., Schapiro, D., Kosa, K., Vass, C., Perez‐Nieves, M., Pierce, A., Poon, J. L., DiBenedetti, D. B., & Mansfield, C. A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01652-0 · Cited by 11
Effect of probiotic extracellular vesicles and their applications on health and disease
Wang, G., Wang, Y., Sheng, K., & Wang, Y. (2025) · Journal of the Science of Food and Agriculture · doi:10.1002/jsfa.14123 · Cited by 11
“121,122 Speci fi c components found in probiotic extracellular vesicles can affect the insulin signaling pathway, enhancing cell sensitivity to insulin and ultimately aiding in blood sugar control.”
Socioeconomic Inequalities in Diabetes Prevalence in Europe
Sidahmed, S., Geyer, S., & Beller, J. (2025) · SAGE Open · doi:10.1177/21582440251316478 · Cited by 10
“Furthermore, demographic factors, such as T2D affecting a broader age range and rising prevalence in aging populations, contribute to its overwhelming predominance (Reed et al., 2021; Vanderniet et al., 2022).”
Venuti, M. T., Roda, E., Brandalise, F., Sarkar, M., Cappelletti, M., Speciani, A. F., Soffientini, I., Priori, E. C., Giammello, F., Ratto, D., et al. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1455434 · Cited by 14
Licinio, J., Licinio, A. W., Busnello, J. V., Ribeiro, L., Gold, P. W., Bornstein, S. R., & Wong, M. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03034-9 · Cited by 11
“In their expert review, Reed et al. state that in recent decades, the number of people with T2D has more than doubled, and the increased global burden of T2D is thought to be due primarily to an increase in obesity over recent decades [11].”
de la Riera, M. D. C. A., Ortolá, R., Kales, S. N., García‐Esquinas, E., Rodríguez‐Artalejo, F., & Sotos‐Prieto, M. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02909-z · Cited by 11
“Although multiple predisposing factors of type 2 diabetes are still under study, obesity has consistently been defined as a major determinant [1, 2].”
InfluentialElnageeb, M. E., Elfaki, I., Adam, M. I. E., Adam, K. M., Alameen, A. O., Elfadl, A. K., Albalawi, I. A., Almasoudi, K. S., Almotairi, R., Alsaedi, B. S. O., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45090471 · Cited by 14
Tvrdá, E., Kováč, J., Benko, F., Ďuračka, M., Varga, A., Uličná, O., Almášiová, V., Capcarová, M., & Chomová, M. (2022) · Open Life Sciences · doi:10.1515/biol-2022-0495 · Cited by 9
“[3], DM2 is nowadays the most prevailing metabolic disease, affecting more than 450 million people worldwide.”
BackgroundSolanki, J., Doshi, R., Virani, N. R., Sheth, N. S., Dhamecha, J., & Shah, C. J. (2022) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_540_22 · Cited by 9
“[5] Small nerve fibers are more susceptible to pathological changes by oxidative stress, ischemia, inflammation that leads to nerve dysfunction and cell break.[19] It can manifest as positive symptoms like pain and negative symptoms like tingling and numbness.”
BackgroundJiang, C. H., Hu, Y., Wang, S., & Chen, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1145067 · Cited by 9
“Subsequently, the duplicates were removed, and the following exclusion criteria were used: (1) conference abstracts; (2) letters to editors; (3) proceedings papers; (4) editorial materials.”
BackgroundMethodHegde, N. C., Kumar, A., Patil, A., Bhattacharjee, S., Gamad, N., Kasudhan, K. S., Kumar, V., & Rastogi, A. (2023) · Acta Diabetologica · doi:10.1007/s00592-023-02126-8 · Cited by 9
“Nearly 600 million people will have DM and associated complications by 2035 [1].”
BackgroundNon-exercise estimated cardiorespiratory fitness and incident type 2 diabetes in adults
Sparks, J. R., Wang, X., Lavie, C. J., Jakicic, J. M., & Sui, X. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111791 · Cited by 10
Hernández-Martín, M., Garcimartín, A., Bocanegra, A., Macho‐González, A., García-Fernández, R. A., de Pascual‐Teresa, S., Redondo‐Castillejo, R., Bastida, S., Sánchez-Muniz, F. J., Benedí, J., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111405 · Cited by 9
RNA Modification in Metabolism
Liu, Y., Sun, Z., Gui, D., Zhao, Y., & Xu, Y. (2025) · MedComm · doi:10.1002/mco2.70135 · Cited by 11
“Its etiology is intricate, encompassing insulin resistance, impaired function of pancreatic β -cells, and disturbances across multiple metabolic pathways [83, 84].”
Ma, J., Chen, W., Vaishnani, D. K., Wang, C., Xue, S., Yang, Q., Tong, Y., Lei, N., Zhao, Z., & Ying, F. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s511372 · Cited by 8
Lanez, E., Bekkar, Y., Bourougaa, L., Benamor, M. L., Bouraoui, R., Boudebia, O., Adaika, A., Nesba, K., Chaoua, H., Bechki, L., et al. (2025) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2025.144239 · Cited by 8
Dandapani, S., & Hwang, Y. (2026) · Mechanobiology · doi:10.1177/29780241261418480 · Cited by 9
Alhallak, I., Quick, C. M., Graham, G. L., & Simmen, R. C. M. (2023) · Reproductive Sciences · doi:10.1007/s43032-023-01190-3 · Cited by 9
“These conditions have distinct pathogenesis: T1DM results from the autoimmune destruction of pancreatic β-cells and hence, early progressive loss of insulin production while T2DM, a condition increasing with age, stems from the loss of insulin sensitivity of target cells, leading to defects in glucose clearance [9, 10…”
Mohanta, B., Sen, D. J., Mahanti, B., & Nayak, A. K. (2023) · Food Bioscience · doi:10.1016/j.fbio.2023.103195 · Cited by 11
Lévuok-Mena, K. P., Patiño-Ladino, O. J., & Prieto-Rodríguez, J. A. (2023) · Scientia Pharmaceutica · doi:10.3390/scipharm91040049 · Cited by 9
“Consequently, several studies highlight the importance of exploring new therapeutic alternatives for the treatment of diabetes and obesity, particularly focusing on the inhibition of digestive enzymes [19].”
BackgroundCurrent State and Principles of Basal Insulin Therapy in Type 2 Diabetes
Vargas‐Uricoechea, H. (2022) · Journal of Clinical Medicine Research · doi:10.14740/jocmr4660 · Cited by 13
“This leads to a state of chronic hyperglycemia and a significant increase in the risk of micro- and macrovascular outcomes [1-3].”
BackgroundKozlova, E. V., Chinthirla, B. D., Bishay, A. E., Perez, P. A., Denys, M. E., Krum, J. M., DiPatrizio, N. V., & Currás‐Collazo, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1049708 · Cited by 7
“The long-lasting changes in glucose and lipid metabolism may be a risk factor for developing T2D and liver steatosis, a clinical condition comorbid with MetS with increasing prevalence in the adult US population (69).”
BackgroundCao, W., Feng, H. Y., Yang, Y.-Y., Wang, L., Wang, X., Ma, Y., Zhao, D., & Hu, X. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-10917-0 · Cited by 8
“The global prevalence and incidence of diabetes have risen dramatically since the beginning of the twenty-first century [25].”
BackgroundPrediabetes and diabetes in India: An HbA1c based epidemiology study
Vora, H., & Kaur, P. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111889 · Cited by 7
Kelly, A., Noctor, E., & van de Ven, P. W. J. (2024) · Procedia Computer Science · doi:10.1016/j.procs.2024.10.363 · Cited by 14
Diabetes Education Program for Nursing Students: A Systematic Review and Meta‐Analysis
Ahn, J., Kim, E., Lee, J. E., & Kim, K. (2024) · Nursing Open · doi:10.1002/nop2.70105 · Cited by 11
Current amyloid inhibitors: Therapeutic applications and nanomaterial-based innovations
López-García, P., Tejero-Ojeda, M. M., Vaquero, M. E., & Carrión‐Vázquez, M. (2025) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2025.102734 · Cited by 8
“T2D has evolved into a global pandemic, primarily characterized by impaired insulin secretion and action, leading to hyperglycemia and numerous cardiometabolic complications (Reed et al., 2021).”
Xing, J.-H., Yang, Y., Lin, T., Hui, X.-Y., & Guo, W.-G. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01730-x · Cited by 7
Pawar, K., Kamble, R. N., & Patil, S. S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.106879 · Cited by 7
Lim, B. S. Y., Chen, M., Li, H., & Li, L. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16442 · Cited by 9
Inthachat, W., Promyos, N., Suttisansanee, U., Chamchan, R., Thangsiri, S., Chantong, B., Pitchakarn, P., & Temviriyanukul, P. (2025) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2025.102130 · Cited by 6
Thanthrige, A. N. W., & Wickramasinghe, N. S. (2025) · JMIR Diabetes · doi:10.2196/80582 · Cited by 12
“However, prediabetes represents a critical window for intervention to prevent the progression to diabetes, with an estimated 70% lifetime risk of developing T2DM [5] without lifestyle or pharmacological interventions [6].”
Khandker, S. S., Kundu, S., Ahmed, F., Khan, A. A., Farhin, L., Islam, F., Begum, R., Uddin, J., & Mamun-Or-Rashid, A. N. M. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48020167 · Cited by 10
“In 2021, approximately 10% of the global adult population, equating to about 537 million individuals, were living with diabetes, a number projected to reach approximately 600 million by 2035 [2,3].”
Salimi, M., Eskandari, F., Binayi, F., Eliassi, A., Ghanbarian, H., Hedayati, M., Fahanik‐Babaei, J., Eftekhary, M., Keyhanmanesh, ., & Zardooz, H. (2022) · Scientific Reports · doi:10.1038/s41598-022-16621-5 · Cited by 7
“The stressors were as follows: (1) transparent plexiglass cylinder (9.”
BackgroundSusilawati, Y., Megantara, S., & Levita, J. (2022) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2022.v14s5.22 · Cited by 9
In Vitro and In Ovo Evaluation of the Potential Hepatoprotective Effect of Metformin
Cozma, G. V., Apostu, A., Macasoi, I. G., Dehelean, C. A., Cretu, O. M., Dinu, Ş., Gaiță, D. I., & Manea, A. M. (2022) · Medicina · doi:10.3390/medicina58060705 · Cited by 7
“This pathology has become a burden for modern society due to the explosion of the number of cases worldwide and multi-organ damage [1].”
BackgroundGiron, M. S. T., & Vega, S. F. D. L. (2022) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.037.02.15 · Cited by 13
Health literacy and adherence to therapy in type 2 diabetes:\na cross-sectional study in Portugal
Rodrigues, S. S. (2019) · Estudo Geral (Universidad de Coimbra) · Cited by 9
Lewallen, C. F., Chien, A. J., Maminishkis, A., Hirday, R., Reichert, D., Sharma, R., Wan, Q., Bharti, K., & Forest, C. R. (2023) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00200.2023 · Cited by 7
The AMPK-SIRT1 Axis: Redefining type 2 diabetes mellitus management
Kemelo, M. K., & Moseki, P. (2025) · Results in Chemistry · doi:10.1016/j.rechem.2025.102139 · Cited by 10
Wang, Y., Cai, S., Wen, W., Tan, Y., Wang, W., Xu, J., & Xiong, P. (2025) · Molecules · doi:10.3390/molecules30051157 · Cited by 7
“Type 1 diabetes is caused by an autoimmune disorder that causes immune cells to attack insulin-producing β cells of the pancreas, mainly in children and adolescents, while T2DM is caused by poor lifestyle, environmental and genetic factors [2,3].”
Bonde, C. G., Tatapudi, H. K., Nikam, R., Bonde, S., & Bhole, R. P. (2025) · Separation Science Plus · doi:10.1002/sscp.70020 · Cited by 6
Prediction of 30-day readmission in diabetes management using Machine learning
Mishra, V., Tanniru, M. R., & Sreedharan, J. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.110616 · Cited by 6
Kouam, A. F., Mofor, S. M., Essam, M. Y. N., Fepa, A. G. K., Zeuko’o, E. M., Seukep, A. J., Ngounou, E., Chuisseu, P. D. D., Moundipa, P. F., & Njayou, F. N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0328974 · Cited by 5
“This disease has quickly become a global health issue, mainly due to high calorie intake, lack of physical activity, inadequate diagnosis, and poor management [1,2].”
Elfaki, I., Mir, R., Tayeb, F. J., Alalawy, A. I., Barnawi, J., Dabla, P. K., & Moawadh, M. S. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303258744231117064253 · Cited by 7
The Relationship Between UA/HDL and Diabetic Peripheral Neuropathy: A Cross-Sectional Analysis
Zhen, R., Wang, S., & Chen, S. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447809 · Cited by 6
Use of amniotic membrane in hard-to-heal wounds: a multicentre retrospective study
Ditmars, F. S., Kay, K. E., Broderick, T. C., & Fagg, W. S. (2024) · Journal of Wound Care · doi:10.12968/jowc.2024.33.sup3.s44 · Cited by 7
Ubaidi, B. A. A., Abdulla, K. J., Jenaidi, N. A. A., Ali, H. A., Marhoon, E. M., Matar, H. M., & Shakeeb, H. (2024) · Clinical Diabetology · doi:10.5603/cd.98550 · Cited by 6
“Type 2 diabetes (T2D) is the most prevalent and clinically significant metabolic disorder, which has recently become a global pandemic and is increasing the healthcare burden worldwide [1].”
Said, F., Omar, A. R., Mohamed, A. S., Dakrory, A. I., & Abdelaziz, M. H. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266308882240806175831 · Cited by 8
Munsakul, N., Manosroi, W., & Buranapin, S. (2024) · Medicina · doi:10.3390/medicina60111833 · Cited by 8
The urinary microbiome in association with diabetes and diabetic kidney disease: A systematic review
Graells, T., Lin, Y., Ahmad, S., Fall, T., & Ärnlöv, J. (2025) · PLoS ONE · doi:10.1371/journal.pone.0317960 · Cited by 6
“Diabetes, especially type 2 diabetes mellitus (T2DM), has become a global health emergency whose prevalence have been rising for decades affecting 537 million people globally in 2021, including 6.7 million related deaths (15,16).”
BackgroundInfluentialNguyen, A., Khafagy, R. T. M., Hashemy, H., Kuo, K. H. M., Roshandel, D., Paterson, A. D., & Dash, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1146099 · Cited by 9
“Further, it provides an average measure of glycemia in the prior 2 to 3 months (1, 12) (1).”
BackgroundAnalysis of the management and therapeutic performance of diabetes mellitus employing special target
Sun, H., & Lin, X.-Y. (2023) · World Journal of Diabetes · doi:10.4239/wjd.v14.i12.1721 · Cited by 10
Pilates for people with type 2 diabetes: A systematic review
González-Devesa, D., Rodríguez, A. O., Blanco-Martínez, N., & Ayán, C. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102922 · Cited by 6
Inflammation and immunological disarrays are associated with acute exercise in type 2 diabetes
Mansouri, V., Vafaee, R., Maram, M. M., Bandarian, F., Sarabi, P., Razi, F., Razzaghi, Z., Tavirani, M. R., Karimi, H., & Rezaei–Tavirani, M. (2024) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01417-3 · Cited by 6
“It is expected that up to 590 million patients will be diagnosed with T2D by 2035 [1].”
Sarkar, A., Khan, A. S., Kaul, R., Lee, S., Kamal, I., Paul, P., Laws, S., & Châari, A. (2024) · Discover Public Health · doi:10.1186/s12982-024-00213-x · Cited by 7
Mahmood, N. M. S., Mahmud, A. M. R., & Maulood, I. M. (2024) · Iraqi Journal of Science · doi:10.24996/ijs.2024.65.8.11 · Cited by 6
“Diabetes mellitus (DM) is recognized as a rapidly growing epidemic with far-reaching implications affecting individuals of all age groups worldwide [1, 2].”
BackgroundMoin, H., Ashraf, R., Butt, B., Mustafa, I., Shafiq, M., & Shah, S. A. R. (2025) · Protein and Peptide Letters · doi:10.2174/0109298665363711250112050930 · Cited by 8
An ethnic-sensitive hybrid framework for T2D prediction with explainable AI and weighted ensembles
Abnoosian, K., Farnoosh, R., Noushkaran, H., Javaheri, D., Shimal, H. A., & Abdulkarem, A. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-31234-4 · Cited by 6
“…study introduces a comprehensive, multi-stage framework for T2D prediction, leveraging diverse datasets including PIDD (768 cases), FHGDD (2,000 records), BDD (465 cases), and custom combinations of these cohorts to capture heterogeneous patient populations from distinct geographical contexts 1–3 .”
Das, S., Awasthi, A., Rawal, R. K., & Bhatia, R. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-025-05549-x · Cited by 8
Alsaidan, A. A., Thirunavukkarasu, A., Alhassan, H. H., Ahmed, I. A. B., Alnasiri, A. S. A., Alhirsan, W., Alazmi, N. N. M., Alkhlaf, A. K., Alderbas, J. M., & Alkhaldi, M. A. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010118 · Cited by 7
“Research shows that T2DM is the most common and clinically crucial pathophysiologic disorder [1,2].”
BackgroundCao, Z., Lei, L., Zhou, Z., Xu, S., Wang, L., Gong, W., Zhang, Q., Pan, B., Zhang, G., Yuan, Q., et al. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae010 · Cited by 5
“Over the past decades, there has been a striking surge in the global occurrence of obesity and type 2 diabetes (T2D), leading to significant social and economic consequences [1].”
Hu, C., Cioana, M., Saini, A., Ragganandan, S., Deng, J., Nadarajah, A., Hou, M., Qiu, Y., Chen, S. S. J., Rivas, A., et al. (2024) · Frontiers in Adolescent Medicine · doi:10.3389/fradm.2024.1303375 · Cited by 5
Differences in brain spindle density during sleep between patients with and without type 2 diabetes
Yeung, D., Talukder, A., Shi, M., Umbach, D. M., Li, Y., Motsinger‐Reif, A. A., Hwang, J. J., Fan, Z., & Li, L. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.109484 · Cited by 8
Comparative evaluation of the antidiabetic potential of three varieties of Ipomoea batatas L.
Akomolafe, S. F., Ajayi, O. O., Agboola, O. E., & Adewale, O. O. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.102015 · Cited by 11
“As of 2021, over 500 million individuals are living with T2DM, spanning all age groups [2,3].”
Hadi, F., Noor, F., Sardar, H., Darwish, H. W., Ashfaq, U. A., Khan, A. A., Daglia, M., & Khan, H. (2025) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2025.108533 · Cited by 5
Vivesh, V., Kaur, B., Jaglan, S., Rani, S., Batra, Y., & Singh, P. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.129018 · Cited by 5
Evaluation of type 1 diabetes mellitus as a risk factor of Parkinson's disease in a Drosophila model
Sanz, F., Martínez‐Carrión, G., Solana‐Manrique, C., & Paricio, N. (2023) · Journal of Experimental Zoology Part A Ecological and Integrative Physiology · doi:10.1002/jez.2726 · Cited by 7
Mir, R., Elfaki, I., Elnageeb, M. E., Moawadh, M. S., Tayeb, F. J., Barnawi, J., Albalawi, I. A., Alharbi, A. A., Alhelali, M. H., & Alsaedi, B. S. O. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13081270 · Cited by 7
“Individuals with type 2 diabetes mellitus (T2D) account for more than 90% of the total number of DM patients [4].”
BackgroundDabhi, B., Mistry, K. N., Thakor, J. M., & Gang, S. D. (2024) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-023-01301-5 · Cited by 5
“Genetic and molecular studies have improved our understanding of the pathophysiology of T2DM and DN in recent years [6, 7].”
Biswas, S., Mita, M. A., Islam, S., Biswas, S., Akhtar‐E‐Ekram, M., Zaman, S., Uddin, M. S., & Saleh, M. A. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109680 · Cited by 5
Assessment of Glycemic Control in Patients With Diabetes in Northern Sudan Using Calculated HbA1c
bagi, O. A., & Ewis, A. A. (2022) · Cureus · doi:10.7759/cureus.33080 · Cited by 5
“Introduction Diabetes mellitus (DM) significantly burdens health services worldwide [1].”
BackgroundVPAC2 receptor mediates VIP-potentiated insulin secretion via ion channels in rat pancreatic β cells
Zhao, X., Deng, L., Ren, L., Yang, H., Wang, B., Zhu, X., Zhang, X., Guo, C., Zhang, Y., & Liu, Y. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113471 · Cited by 7
Song, L., Wang, X., Sun, J., Hu, X., Li, H., Hu, P., & Liu, D. (2023) · Clinical Pharmacokinetics · doi:10.1007/s40262-022-01209-z · Cited by 5
“, overweight, smoking, and inactive lifestyle [2].”
BackgroundKrishnakumar, H., Manikandan, J., Prabhu, D., & Jeyakanthan, J. (2024) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2024.2443844 · Cited by 4
“…(WHO) defines diabetes as a metabolic disorder arising from multiple causes, characterized by prolonged elevated blood sugar levels and imbalances in the metabolism of carbohydrates, fats, and proteins, due to issues with insulin secretion, insulin effectiveness, or a combination of both [2].”
Liu, H.-Y., Xiang, J., Xie, Q., & Xiang, H. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.119879 · Cited by 4
Bertalan, P. M., Nokhoijav, E., Pap, Á., Neagu, G. C., Káplár, M., Darula, Z., Kalló, G., Prókai, L., & Csősz, É. (2025) · Proteomes · doi:10.3390/proteomes13040067 · Cited by 5
“However, the major risk factor for the development of T2D is obesity, which is arising with an increasing tendency as a consequence of unhealthy lifestyle choices, such as excessive dietary intake and a lack of physical activity, leading to an increase in body weight [1,2,6–8].”
Ahmmed, R., Antu, U. S., Noor, T., Faysal, M. F., Sarker, A., Mahmud, S., Ajadee, A., & Mollah, M. N. H. (2026) · Journal of Genetic Engineering and Biotechnology · doi:10.1016/j.jgeb.2026.100667 · Cited by 4
In Vitro Anti-diabetic Activity of Pomegranate Peel Extract-Mediated Strontium Nanoparticles
Parthasarathy, P. R., Varshan, I., & Shanmugam, R. (2023) · Cureus · doi:10.7759/cureus.51356 · Cited by 20
“The International Diabetes Federation estimates that there are currently 40.9 million people with diabetes worldwide, and this number is expected to increase to 60.9 million by 2025 and possibly quadruple by 2030 [1].”
BackgroundInfluentialGlobal burden of type 2 diabetes in adolescents from 1990 to 2019
Luo, J., Hou, J., Yi, J., Li, L., & Zhao, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1405739 · Cited by 6
Dholariya, M. P., & Patel, A. S. (2024) · Chemistry Letters · doi:10.1093/chemle/upae162 · Cited by 4
Douae, B., Bikri, S., Aboubi, M. E., Yassif, F.-Z., & Aboussaleh, Y. (2025) · Biological Trace Element Research · doi:10.1007/s12011-025-04640-y · Cited by 4
“T2DM is typically characterized by chronic hyperglycemia, insulin resistance, and progressive beta-cell dysfunction [23].”
Gao, M., Gong, L., Zeng, Y., Li, D., Wen, J., Guo, Y., Li, Z., Luo, J., Chen, C., & Wen, G. (2025) · Frontiers in Neuroimaging · doi:10.3389/fnimg.2025.1615654 · Cited by 4
“Notably, more than 90% of patients with type 2 diabetes are associated with overweight or obesity, emphasizing the critical role of dysregulated energy intake and obesity in disease progression (Reed et al., 2021).”
Joblin-Mills, A., Wu, Z. E., Fraser, K., Jones, B., Yip, W. C. Y., Lim, J. J., Lu, L. W., Sequeira, I. R., & Poppitt, S. (2022) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2022.980856 · Cited by 6
“The prevalence of type 2 diabetes (T2D) in China has increased drastically in recent decades, reaching epidemic proportions (1).”
BackgroundLeukocyte metabolism in obese type 2 diabetic individuals associated with COVID-19 severity
Lobato, T. B., Gennari-Felipe, M., Pauferro, J. R. B., Correa, I. S., Santos, B. F., Dias, B. B., Borges, J. C. D. O., dos Santos, C. S., Santos, E. S. D. S., de Araújo, M. J. L., et al. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1037469 · Cited by 5
“DMs occur after a period characterized by reduced insulin sensitivity, also known as IR, chronic hyperglycemia, and consequent pancreatic beta cell dysfunction with possible progression to cell death and disease onset (Kahn, 2003; Reed et al., 2021).”
BackgroundHOMA-IR and HOMA2-IR estimation based on glycated hemoglobin as an alternative for fasting glucose
Delanghe, J., Verlinde, E., Speeckaert, M. M., & Maenhout, T. M. (2022) · Acta Clinica Belgica · doi:10.1080/17843286.2022.2160889 · Cited by 5
“Insulin sensitivity is a hallmark of prediabetes and diabetes mellitus type 2, which is a growing health problem [1].”
BackgroundJermy, B. R., Salahuddin, M., Tanimu, G., Dafalla, H., Almofty, S. A., & Ravinayagam, V. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020593 · Cited by 4
Method development and validation of Metformin HCL and Dapagliflozin by using RP-HPLC
Siddique, W., Zulcaif, Umar, H., Usmani, S. J., Waqas, M., Gul, M., & Gul, M. (2024) · Acta Chromatographica · doi:10.1556/1326.2024.01226 · Cited by 4
Hsouna, A. B., Chahdoura, H., Mekinić, I. G., Maisto, M., Kukuła‐Koch, W., Zeljkovıć, S. Ć., Koch, W., Akacha, B. B., Bouteraa, M. T., Belgacem, A. B., et al. (2024) · South African Journal of Botany · doi:10.1016/j.sajb.2024.09.027 · Cited by 7
Zhao, H., Yin, R., Wang, Y., Wang, Z., Zhang, L., Xu, Y., Wang, D., Wu, J., Wei, L., Yang, L., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-77996-1 · Cited by 6
Role of functional foods in diabetes management
Azmat, F., Naseer, M. S., Safdar, M., Bishoyi, A. K., Islam, F., Imran, A., Kanwal, N., Zahra, D. E., Kalia, R., & Zafar, A. (2024) · Nutrire · doi:10.1186/s41110-024-00304-4 · Cited by 4
“This number is anticipated to increase to > 590 million by 2035 [13].”
Rani, R., Singh, N., Madhubabu, P., Rekha, M. M., Kaur, M., Soothwal, P. K., Arora, I., Kumar, M., Chauhan, A. S., Gaur, A., et al. (2025) · BioNanoScience · doi:10.1007/s12668-025-02089-w · Cited by 5
“High blood glucose levels induce diabetes, which may have serious consequences, including blindness, renal failure, diabetic ketoacidosis, cardiovascular disease, and stroke [56].”
Niba, L. L., Dzekem, A. Y., Navti, L. K., & Samje, M. (2023) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2023.114013 · Cited by 4
Wang, P., Liu, Y., Kang, S. Y., Lyu, C., Han, X., Ho, T., Lee, K. J., Meng, X., Park, Y., & Jung, H. W. (2023) · Chinese Journal of Integrative Medicine · doi:10.1007/s11655-023-3548-9 · Cited by 4
Metadata
- Authors
- Reed, J., Bain, S., & Kanamarlapudi, V.
- Affiliations
- Swansea University (GB)
- Corresponding author
- Reed, Josh
- Bain, Stephen
- Kanamarlapudi, Venkateswarlu
- Venue
- Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
- Publisher
- Informa UK Limited
- Published
- 2021-08
- Volume
- Volume 14
- Pages
- 3567-3602
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC8369920
- OpenAlex
- W3191601669
- Cited by
- 441
- References
- 326
- Citations by year
- 2026: 73 · 2025: 109 · 2024: 107 · 2023: 98 · 2022: 51 · 2021: 2
- FWCI
- 9.88
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Directorate for Biological Sciences
- Medical Research Council (G0401232)
- Biotechnology and Biological Sciences Research Council (BB/S019588/1, BB/F017596/1, BB/C515455/2, 1095087)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, diabetes epidemiology, diabetes aetiology, diabetes pathogenesis, impaired insulin secretion, glucagon-like peptide-1, incretins, GLP-1 receptor agonists, bariatric surgery alternatives, weight loss, diabetes complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.